1.09
0.02 (1.87%)
| Previous Close | 1.07 |
| Open | 1.06 |
| Volume | 69,348 |
| Avg. Volume (3M) | 97,863 |
| Market Cap | 68,245,336 |
| Price / Sales | 1.57 |
| Price / Book | 5.08 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Profit Margin | -45.59% |
| Operating Margin (TTM) | -44.54% |
| Diluted EPS (TTM) | -0.290 |
| Quarterly Revenue Growth (YOY) | -2.90% |
| Total Debt/Equity (MRQ) | 185.50% |
| Current Ratio (MRQ) | 2.61 |
| Operating Cash Flow (TTM) | -13.06 M |
| Levered Free Cash Flow (TTM) | -9.67 M |
| Return on Assets (TTM) | -20.46% |
| Return on Equity (TTM) | -96.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Cytosorbents Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.13 |
|
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 15.29% |
| % Held by Institutions | 27.77% |
| 52 Weeks Range | ||
| Median | 10.00 (817.43%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 16 Sep 2025 | 10.00 (817.43%) | Buy | 0.939 |
| 20 Aug 2025 | 10.00 (817.43%) | Buy | 0.894 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |